Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2009 December;100(6) > Minerva Medica 2009 December;100(6):447-58

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,878


eTOC

 

REVIEWS  VIRAL DISEASES


Minerva Medica 2009 December;100(6):447-58

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Therapy of chronic hepatitis B: new goals and new treatments

Mauss S.

Center for HIV and Hepatogastroenterology, Duesseldorf, Germany


PDF  


Treatment of chronic hepatitis B has shown a rapid development in the last years leading to a shift of treatment strategies from interferon to hepatitis B virus (HBV)-polymerase inhibitors. In particular, treatment with HBV-polymerase inhibitors has changed the indication on how to treat a patient and when to stop therapy. Long-term treatment with HBV-polymerase inhibitors may often be required, even if it raises the possibility of resistance and subsequent treatment failure. This review provides a strategy on how to manage HBV therapy with the currently available treatment options.

top of page

Publication History

Cite this article as

Corresponding author e-mail

stefan.mauss@center-duesseldorf.de